Community Corner

The drug, called Dimebon, failed in its first late-stage clinical trial, dealing a blow to patients with Alzheimer’s and the companies developing the treatment, Medivation and Pfizer.

The drug, called Dimebon, failed in its first late-stage clinical trial, dealing a blow to patients with Alzheimer’s and the companies developing the treatment, Medivation and Pfizer.

More than half the nation’s residency programs to train doctors in internal medicine accepted drug industry money, a survey found.

Billy Tauzin, the industry’s top lobbyist, thought it was a smart move to bet on health care reform early — only to watch it come to a screeching halt.

Without the regulatory certainty stemming from the health care bill, drug companies face unpleasant surprises like a heavier tax on foreign income.

As wealthy nations try to get rid of surpluses, most poorer countries still lack access to the H1N1 vaccine.

Dr. Leslie Baumann’s comments in the media about an antiwrinkle drug violated restrictions on drug promotion, the agency said, in what is believed to be the first time an individual investigator was warned.

European and American drug regulators had two starkly different reactions this week to data on an obesity drug.

Thwarted research means there is no good scientific evidence that legalizing marijuana’s use provides any benefits over current therapies.

Chronic myelogenous leukemia has been transformed from deadly to nearly always treatable.